Hepatitis C: After the Diagnosis

Slides:



Advertisements
Similar presentations
Hcv infection and management in advanced liver disease
Advertisements

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.
Acute Viral Hepatitis. Viral Hepatitis Infectious: Hepatitis A Infectious: Hepatitis A Serum : Hepatitis B, D Serum : Hepatitis B, D NANB : Hepatitis.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
V.E.I.L. Liver Cancer Prevention. 1. Vaccination Birth dose + 2 Universal for those not already chronics Screening pregnant women Catch up vaccination.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,
Non-Invasive Liver Testing
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Treatment of HBV/HCV Coinfection
Role of Ministry of Health and Medical Education in management and control of Hepatitis C 2016/07/13.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Addressing Viral Hepatitis
Volume 63, Issue 1, Pages (July 2015)
Achieving WHO Recommendations for HCV in the European Union
Achieving WHO Recommendations for HCV Elimination in the Eastern Mediterranean Region I. Waked April 12, 2016.
HCV & liver transplantation
University of Medicine and Pharmacy “Carol Davila”, Bucharest
THE APP THAT ALLOWS EVERY DOCTOR TO PRACTICE:
DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV
Department of Veterans Affairs
Talking to Patients About HCV Treatment
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Chronic Hepatitis C Virus Infection
Starting Strong: Initial Evaluation of the Patient With HCV
HCV: Who Should We Screen and Why?
More Than Meets the Eye: Identifying Who Is at Risk for NASH
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Case 53-year-old Black Man
Expanding the Universe of Viral Hepatitis Treaters
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
HIV Management: An Update on the Latest EACS Guidelines
More Than Treatment.
HCV Screening.
HBV Infection: Some Sobering Facts
Evaluation of the Patient With HCV Infection
Out With the Old and In With the New, Again?
Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
HCV Protease Inhibitors in Clinical Practice
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Figure 1 Proposed algorithm for the management
Virological tools to diagnose and monitor hepatitis C virus infection
Care of the Treatment-naive Patient With HCV/HIV Coinfection
Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Impact of metabolic risk factors on HCC
From non-A, non-B hepatitis to hepatitis C virus cure
Managing Age-Related Clinical Issues in Hemophilia
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
What Does the Future Hold and What Will It Mean for Patients?
Assessing the Burden of Hyperkalemia
Disease Burden of VTE Phases of VTE Treatment.
Epidemiology of socially significant infectious diseases (TB, HIV-infection, viral hepatitis C and B) in Russia Olga Nechaeva Expert of the Expert Group.
Volume 63, Issue 1, Pages (July 2015)
Assessing the Burden of Hyperkalemia
Volume 142, Issue 6, Pages e4 (May 2012)
Removing Barriers in the HCV Cascade of Care
Managing Hepatitis C in Vermont
Managing Hepatitis C in Vermont
Multimodal Approaches to Cracking the Code in Low Back Pain
Presentation transcript:

Hepatitis C: After the Diagnosis

New Therapies Can Cure 95% of Patients With HCV Infection

Treatment of HCV Infection Cure, Risk Reduction, and Decreased All-Cause Mortality

Patient History Clues to the Source and Timing of Acquisition of Infection

Treatment History: Naive or Experienced A Critical Factor in Selection of Treatment Regimen

Diagnosing HCV Infection

HCV Genotype Matters A Factor in Response to Treatment

Pretreatment Screening

Assess for Stigmata of Chronic Liver Disease

Additional Work-ups

Vibration-Controlled Transient Elastography

Serum Markers of Liver Fibrosis

Pretreatment Considerations

The ABCs of Viral Hepatitis

Patients With Chronic HCV Infection Should Be Vaccinated

Burden of Disease

Steatosis Fatty Liver

Abbreviations

References

References (cont)

References (cont)